Opinion

The shift by agencies away from the current guidelines on mergers and acquisitions has left firms in limbo.

By pushing for deregulation and adopting other reforms, President Carter left an enduring legacy on the U.S. regulatory system.

Anti-abortion advocates take aim at FDA approval and regulation of the abortion drug mifepristone, threatening access nationwide.

FDA’s approach to evidence-based decision-making may not be addressed to the right people.

New agency sets example for state and federal agencies to follow in analyzing regulatory costs and benefits.

Examining countries’ net-zero pledges reveals variations and loopholes that will allow for slippage in climate progress.

Restricting gas-powered leaf blowers can positively affect the health of people and the planet.

Private rights of action lead agencies to seek greater policy control through rulemaking.

The U.S. public prefers electric vehicle tax credits be open to cars manufactured anywhere.

Climate disclosures—if designed well—can bridge the gap between financial actors and regulatory goals.

The Federal Trade Commission should develop a nuanced approach to employee noncompete agreements.

To protect consumers, governments should step in to address the risks of DNA testing.